Autopsy report · NCT05247307

Efficacy of the Infusion of Donor Plasma in COVID-19 Infection

“Lack of efficacy of treatment tested”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 11 months after it had already started.
• Ran for about 1 year 9 months before it stopped.
• 93 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Hospital Galdakao-Usansolo

Sponsor type

Government (non-US federal)

Conditions

COVID-19

Interventions

convalescent plasma infusion covid 19

Participants

93

Sites

1

Countries

Spain

Trials that died the same way

• A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors
  “Lack of efficacy” (77% match in meaning)
• Topical Garlic Concentrate for Alopecia Areata in Children
  “Lack of efficacy of the study medication” (74% match in meaning)
• Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin
  “The study had poor efficacy.” (73% match in meaning)
• Cross Linking for Treatment of Corneal Infection
  “insufficient efficacy” (72% match in meaning)
• A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer
  “Study stopped due to lack of efficacy.” (71% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.